What is Leerink Partnrs’ Estimate for ABVX FY2029 Earnings?

ABIVAX Société Anonyme (NASDAQ:ABVX) – Equities researchers at Leerink Partnrs issued their FY2029 earnings per share estimates for ABIVAX Société Anonyme in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.17) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.92) per share.

A number of other brokerages have also recently issued reports on ABVX. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $38.67.

ABIVAX Société Anonyme Stock Up 3.1 %

ABVX stock opened at $6.03 on Thursday. The stock’s 50 day simple moving average is $7.08 and its 200 day simple moving average is $9.52. ABIVAX Société Anonyme has a fifty-two week low of $5.49 and a fifty-two week high of $17.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC bought a new position in shares of ABIVAX Société Anonyme during the 4th quarter worth approximately $29,000. R Squared Ltd purchased a new stake in shares of ABIVAX Société Anonyme during the fourth quarter valued at approximately $36,000. BNP Paribas Financial Markets lifted its holdings in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the period. Walleye Capital LLC boosted its position in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the last quarter. Finally, abrdn plc grew its stake in ABIVAX Société Anonyme by 34.1% in the 4th quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after purchasing an additional 107,750 shares during the period. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.